biotech2 hours ago
Iovance shares slide as lifileucel data shows mixed results across lung cancer subgroups
Iovance Biotherapeutics shares fell approximately 6% to 9% on October 29, 2026, after the company released Phase 2 data for its lung cancer therapy, lifileucel. While the overall response rate was 25%, consistent with prior reports, the data revealed a stark divide: patients with specific genetic profiles and smoking histories achieved a 59% success rate, whereas those with KRAS mutations saw minimal benefit. The company plans to launch a new trial arm in November 2026 targeting this high-response group and aims to file for FDA approval in 2027. The stock pullback follows a sharp overnight gain and reflects investor caution regarding valuation and the narrow applicability of the treatment.